OrbiMed’s Protara Therapeutics TARA Stock Holding History

OrbiMed’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.48M	Buy	+2,220,000	New	+$10.6M	0.16%	87
2023 Q4	–	Sell	-772,584	Closed	-$1.29M	–	131
2023 Q3	$1.29M	Hold	772,584	–	–	0.03%	118
2023 Q2	$1.85M	Sell	772,584 -20,974	-3%	-$62.3K	0.03%	117
2023 Q1	$2.48M	Sell	793,558 -37,083	-4%	-$123K	0.05%	111
2022 Q4	$2.23M	Hold	830,641	–	–	0.04%	102
2022 Q3	$2.46M	Hold	830,641	–	–	0.05%	119
2022 Q2	$2.43M	Hold	830,641	–	–	0.04%	127
2022 Q1	$4.25M	Hold	830,641	–	–	0.07%	124
2021 Q4	$5.61M	Buy	830,641 +380,641	+85%	+$2.62M	0.07%	131
2021 Q3	$3.11M	Hold	450,000	–	–	0.03%	163
2021 Q2	$4.38M	Hold	450,000	–	–	0.04%	150
2021 Q1	$7.08M	Hold	450,000	–	–	0.07%	132
2020 Q4	$10.9M	Hold	450,000	–	–	0.1%	121
2020 Q3	$7.57M	Buy	+450,000	New	+$10.4M	0.1%	116

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

OrbiMed's TARA Position: Q2 2026 in Review

OrbiMed opened a new position in Protara Therapeutics (TARA) in Q2 2026: 2,220,000 shares worth $8.48M. The stake represents 0.16% of the portfolio and ranks #87 among its holdings. This is a return to the name: OrbiMed previously reported a position in TARA as recently as Q3 2023.

OrbiMed first reported a position in TARA in Q3 2020 and has held it in 14 quarters since. The position peaked at $10.9M in Q4 2020. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

OrbiMed held 2,220,000 shares of Protara Therapeutics worth $8.48M as of Q2 2026.
Protara Therapeutics was a new OrbiMed position in Q2 2026.
Protara Therapeutics made up 0.16% of OrbiMed's portfolio in Q2 2026, its #87 holding.
OrbiMed first reported a position in Protara Therapeutics in Q3 2020 and has held it in 14 quarters since.
OrbiMed's Protara Therapeutics position peaked at $10.9M in Q4 2020.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.